JQ1 is a chemical compound which is under development as a non-hormonal male contraceptive drug. Its chemical structure is a triazolothienodiazepine, a series originally discovered by Mitsubishi Pharma [WO/2009/084693], related to benzodiazepinederivatives such as etizolam, however JQ1 does not produce sedative or anxiolytic effects and is instead a potent and selective inhibitor of the bromodomain testis-specific protein BRDT, which is essential for chromatin remodeling during spermatogenesis.